Ident. | Authors (with country if any) | Title |
---|
000087 |
Fabrizio Stocchi [Italie] ; Olivier Rascol ; Alain Destée [France] ; Nobutaka Hattori ; Robert A. Hauser ; Anthony E. Lang ; Werner Poewe [Autriche] ; Mark Stacy ; Eduardo Tolosa ; Haitao Gao ; Jennifer Nagel ; Martin Merschhemke ; Ana Graf ; Christopher Kenney ; Claudia Trenkwalder | AFQ056 in Parkinson patients with levodopa-induced dyskinesia: 13-week, randomized, dose-finding study. |
000098 |
Bruno Dubois [France] ; Eduardo Tolosa ; Regina Katzenschlager ; Murat Emre ; Andrew J. Lees ; Günther Schumann ; Emmanuelle Pourcher ; Julian Gray ; Gail Thomas ; Jina Swartz ; Timothy Hsu ; Margaret L. Moline | Donepezil in Parkinson's disease dementia: a randomized, double-blind efficacy and safety study. |
000147 |
Eric Bardinet [France] ; Hayat Belaid [France] ; David Grabli [France] ; Marie-Laure Welter [France] ; Sara Fernandez Vidal [France] ; Damien Galanaud [France] ; Stéphane Derrey [France] ; Didier Dormont [France] ; Philippe Cornu [France] ; Jérôme Yelnik [France] ; Carine Karachi [France] | Thalamic stimulation for tremor: Can target determination be improved? |
000157 |
Cristina Sampaio [Portugal] ; Juliana Bronzova [Pays-Bas] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Serge V. Van De Witte [Pays-Bas] ; And Ad Theeuwes [Pays-Bas] | Pardoprunox in early Parkinson's disease: Results from 2 large, randomized double‐blind trials |
000179 |
Estelle Dellapina [France] ; Angélique Gerdelat-Mas [France] ; Fabienne Ory-Magne [France] ; Laure Pourcel [France] ; Monique Galitzky [France] ; Fabienne Calvas [France] ; Marion Simonetta-Moreau [France] ; Claire Thalamas [France] ; Pierre Payoux [France] ; Christine Brefel-Courbon [France] | Apomorphine effect on pain threshold in Parkinson's disease: A clinical and positron emission tomography study |
000199 |
Anthony H. V. Schapira [Royaume-Uni] ; Stefan Albrecht [Allemagne] ; Paolo Barone [Italie] ; Cynthia L. Comella [États-Unis] ; Michael P. Mcdermott [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Olivier Rascol [France] ; Kenneth Marek [États-Unis] | Rationale for delayed‐start study of pramipexole in Parkinson's disease: The PROUD study |
000200 |
Robert A. Hauser [États-Unis] ; Anthony H. V. Schapira [Royaume-Uni] ; Olivier Rascol [France] ; Paolo Barone [Italie] ; Yoshikuni Mizuno [Japon] ; Laurence Salin [France] ; Monika Haaksma [Autriche] ; Nolwenn Juhel [France] ; Werner Poewe [Autriche] | Randomized, double‐blind, multicenter evaluation of pramipexole extended release once daily in early Parkinson's disease |
000206 |
Olivier Rascol [France] ; Jean-Philippe Azulay [France] ; Olivier Blin [France] ; Anne-Marie Bonnet [France] ; Christine Brefel-Courbon [France] ; Pierre Césaro [France] ; Philippe Damier [France] ; Bérengère Debilly [France] ; Frank Durif [France] ; Monique Galitzky [France] ; Jean-Marie Grouin [France] ; Sylvie Pennaforte [France] ; Gabriel Villafane [France] ; Sadek Yaici [France] ; Yves Agid [France] | Orodispersible sublingual piribedil to abort OFF episodes: A single dose placebo‐controlled, randomized, double‐blind, cross‐over study |
000209 |
Elena Moro [Canada] ; Andres M. Lozano [Canada] ; Pierre Pollak [France] ; Yves Agid [France] ; Stig Rehncrona [Suède] ; Jens Volkmann [Allemagne] ; Jaime Kulisevsky [Espagne] ; Jose A. Obeso [Espagne] ; Alberto Albanese [Italie] ; Marwan I. Hariz [Royaume-Uni, Suède] ; Niall P. Quinn [Royaume-Uni] ; Jans D. Speelman [Pays-Bas] ; Alim-Louis Benabid [France] ; Valerie Fraix [France] ; Alexandre Mendes [France] ; Marie-Laure Welter [France] ; Jean-Luc Houeto [France] ; Philippe Cornu [France] ; Didier Dormont [France] ; Annalena L. Tornqvist [Suède] ; Ron Ekberg [Suède] ; Alfons Schnitzler [Allemagne] ; Lars Timmermann [Allemagne] ; Lars Wojtecki [Allemagne] ; Andres Gironell [Espagne] ; Maria C. Rodriguez-Oroz [Espagne] ; Jorge Guridi [Espagne] ; Anna R. Bentivoglio [Italie] ; Maria F. Contarino [Italie, Pays-Bas] ; Luigi Romito [Italie] ; Massimo Scerrati [Italie] ; Marc Janssens [Pays-Bas] ; Anthony E. Lang [Canada] | Long‐term results of a multicenter study on subthalamic and pallidal stimulation in Parkinson's disease |
000217 |
Olivier Rascol [France] ; Paolo Barone [Italie] ; Robert A. Hauser [États-Unis] ; Yoshikuni Mizuno [Japon] ; Werner Poewe [Autriche] ; Anthony H. V. Schapira [Royaume-Uni] ; Laurence Salin [France] ; Mandy Sohr [Allemagne] ; Catherine Debieuvre [France] | Efficacy, safety, and tolerability of overnight switching from immediate‐ to once daily extended‐release pramipexole in early Parkinson's disease |
000219 |
Juliana Bronzova [Pays-Bas] ; Cristina Sampaio [Portugal] ; Robert A. Hauser [États-Unis] ; Anthony E. Lang [Canada] ; Olivier Rascol [France] ; Ad Theeuwes [Pays-Bas] ; Serge V. Van De Witte [Pays-Bas] ; Guus Van Scharrenburg [Pays-Bas] | Double‐blind study of pardoprunox, a new partial dopamine agonist, in early Parkinson's disease |
000231 |
Nir Giladi [Israël] ; Joseph Tal [Israël] ; Tali Azulay [Israël] ; Olivier Rascol [France] ; David J. Brooks [Royaume-Uni] ; Eldad Melamed [Israël] ; Wolfgang Oertel [Allemagne] ; Werner Poewe [Autriche] ; Fabrizio Stocchi [Italie] ; Eduardo Tolosa [Espagne] | Validation of the freezing of gait questionnaire in patients with Parkinson's disease |
000249 |
David Grabli [France] ; Claire Ewenczyk [France] ; Maria-Clara Coelho-Braga [France] ; Christelle Lagrange [France] ; Valerie Fraix [France] ; Philippe Cornu [France] ; Alim-Louis Benabid [France] ; Marie Vidailhet [France] ; Pierre Pollak [France] | Interruption of deep brain stimulation of the globus pallidus in primary generalized dystonia |
000298 |
David Devos [France] ; Kathy Dujardin [France] ; Isabelle Poirot [France] ; Caroline Moreau [France] ; Olivier Cottencin [France] ; Pierre Thomas [France] ; Alain Destée [France] ; Regis Bordet [France] ; Luc Defebvre [France] | Comparison of desipramine and citalopram treatments for depression in Parkinson's disease: A double‐blind, randomized, placebo‐controlled study |
000308 |
C. Warren Olanow [États-Unis] ; Robert A. Hauser [États-Unis] ; Joseph Jankovic [États-Unis] ; William Langston [États-Unis] ; Anthony Lang [Canada] ; Werner Poewe [Autriche] ; Eduardo Tolosa [Espagne] ; Fabrizio Stocchi [Italie] ; Eldad Melamed [Israël] ; Eli Eyal [Israël] ; Olivier Rascol [France] | A randomized, double‐blind, placebo‐controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (the ADAGIO study): Rationale, design, and baseline characteristics |
000314 |
Robert A. Hauser [États-Unis] ; Olivier Rascol [France] ; Amos D. Korczyn [Israël] ; A. Jon Stoessl [Canada] ; Ray L. Watts [États-Unis] ; Werner Poewe [Autriche] ; Peter P. De Deyn [Belgique] ; Anthony E. Lang [Canada] | Ten‐year follow‐up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa |
000317 |
Christopher G. Goetz [États-Unis] ; Philippe Damier [France] ; Christine Hicking [Allemagne] ; Eugene Laska [États-Unis] ; Thomas Müller [Allemagne] ; C. Warren Olanow [États-Unis] ; Olivier Rascol [France] ; Hermann Russ [Allemagne] | Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double‐blind placebo‐controlled trial |
000318 |
Björn Holmberg [Suède] ; Jan-Ove Johansson [Suède] ; Werner Poewe [Autriche] ; Gregor Wenning [Autriche] ; Niall P. Quinn [Royaume-Uni] ; Chris Mathias [Royaume-Uni] ; Eduardo Tolosa [Espagne] ; Adriana Cardozo [Espagne] ; Nil Dizdar [Suède] ; Olivier Rascol [France] ; Tarik Slaoui [France] | Safety and tolerability of growth hormone therapy in multiple system atrophy: A double‐blind, placebo‐controlled study |
000322 |
Robert A. Hauser [États-Unis] ; Laurence Salin [France] ; Nolwenn Juhel [France] ; Victor L. Konyago [États-Unis] | Randomized trial of the triple monoamine reuptake inhibitor NS 2330 (tesofensine) in early Parkinson's disease |
000353 |
Alexandre Castro-Caldas [Portugal] ; Paul Delwaide [Belgique] ; Wolfgang Jost [Allemagne] ; Marcelo Merello [Argentine] ; Adrian Williams [Royaume-Uni] ; Paolo Lamberti [Italie] ; Miguel Aguilar [Espagne] ; Susanna Del Signore [France] ; Pierre Cesaro [France] | The Parkinson–Control study: A 1‐year randomized, double‐blind trial comparing piribedil (150 mg/day) with bromocriptine (25 mg/day) in early combination with levodopa in Parkinson's disease |
000357 |
Wolfgang H. Oertel [Allemagne] ; Erik Wolters [Pays-Bas] ; Cristina Sampaio [Portugal] ; Santiago Gimenez-Roldan [Espagne] ; Bruno Bergamasco [Italie] ; Max Dujardin [France] ; Donald G. Grosset [Royaume-Uni] ; Guy Arnold [Allemagne] ; Klaus L. Leenders [Pays-Bas] ; Hans-Peter Hundemer [États-Unis] ; Alberto Lled [États-Unis] ; Andrew Wood [États-Unis] ; Paul Frewer [États-Unis] ; Johannes Schwarz [Allemagne] | Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study |
000369 |
Olivier Rascol [France] ; Bruno Dubois [France] ; Alexandre Castro Caldas [Portugal] ; Stephen Senn [Royaume-Uni] ; Susanna Del Signore [France] ; Andrew Lees (neurologue) [Royaume-Uni] | Early piribedil monotherapy of Parkinson's disease: A planned seven‐month report of the REGAIN study |
000424 |
Jan C. M. Zijlmans [Royaume-Uni, Pays-Bas] ; Berengere Debilly [France] ; Olivier Rascol [France] ; Andrew Lees (neurologue) [Royaume-Uni] ; Franck Durif [France] | Safety of entacapone and apomorphine coadministration in levodopa‐treated Parkinson's disease patients: Pharmacokinetic and pharmacodynamic results of a multicenter, double‐blind, placebo‐controlled, cross‐over study |
000455 |
Marc Ziegler ; Alexandre Castro-Caldas [Portugal] ; Susanna Del Signore [France] ; Olivier Rascol [France] | Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6‐month, randomized, placebo‐controlled study |
000552 |
Jean-Louis Montastruc [France] ; Marc Ziegler [France] ; Olivier Rascol [France] ; Muriel Malbezin [France] | A randomized, double‐blind study of a skin patch of a dopaminergic agonist, piribedil, in Parkinson's disease |
000560 |
Korczyn [Israël] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Warner H. Poewe [Autriche] ; Olivier Rascol [France] ; Fabrizzio Stocchi [Italie] | Ropinirole versus bromocriptine in the treatment of early Parkinson's disease: A 6‐month interim report of a 3‐year study |
000561 |
Rascol [France] ; David J. Brooks [Royaume-Uni] ; Ehrout R. Brunt [Pays-Bas] ; Amos D. Korczyn [Israël] ; Warner H. Poewe [Autriche] ; Fabrizzio Stocchi [Italie] | Ropinirole in the treatment of early Parkinson's disease: A 6‐month interim report of a 5‐year levodopa‐controlled study |
000569 |
Rascol [France] ; Kasia Sieradzan [Royaume-Uni] ; Hélène Peyro-Saint-Paul [France] ; Claire Thalamas [France] ; Christine Brefel-Courbon [France] ; Jean Michel Senard [France] ; Philippe Ladure [France] ; Jean Louis Montastruc [France] ; Andrew Lees (neurologue) [Royaume-Uni] | Efaroxan, an alpha‐2 antagonist, in the treatment of progressive supranuclear palsy |
000629 |
Rascol [France] ; Nelly Fabre [France] ; Olivier Blin [France] ; Janet Poulik [France] ; Umberto Sabatini [France] ; Jean-Michel Senard [France] ; Michèle Ané [France] ; Jean-Louis Montastruc [France] ; André Rascol [France] | Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease |
000647 |
H. Allain [France] ; Pierre Pollak [France] ; H. C. Neukirch [France] | Symptomatic effect of selegiline in De Novo Parkinsonian patients |
000652 |
Jean-Fra Ois De Saint Victor [France] ; Pierre Pollak [France] ; Claire-Lise Gervason [France] ; Jean Perret [France] | Levodopa‐induced diphasic dyskinesias improved by subcutaneous apomorphine |